NeurAxis develops neuromodulation therapies to address chronic and debilitating conditions in children.
NeurAxis has raised $2.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
NeurAxis's investors include Flagstaff International.
NeurAxis is headquartered in Carmel, United States.
NeurAxis develops neuromodulation therapies to address chronic and debilitating conditions in children.
NeurAxis is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NeurAxis — Funding & Investors." VCBacked, October 1, 2025, https://www.vcbacked.co/company/neuraxis. Accessed September 30, 2026.
VCBacked. (2025). NeurAxis — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/neuraxis
{{cite web |title=NeurAxis — Funding & Investors |url=https://www.vcbacked.co/company/neuraxis |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated